
nContact Surgical
Total Raised
$47.9MInvestors Count
10Deal Terms
3Funding, Valuation & Revenue
9 Fundings
nContact Surgical has raised $47.9M over 9 rounds.
nContact Surgical's latest funding round was a Acquired for on October 5, 2015.
nContact Surgical's latest post-money valuation is from October 2015.
Sign up for a free demo to see nContact Surgical's valuations in October 2015 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
10/5/2015 | Acquired | 7 | ||||
3/8/2013 | Series E | |||||
1/23/2012 | Debt - II | |||||
11/11/2010 | Series D | |||||
8/5/2010 | Debt |
Date | 10/5/2015 | 3/8/2013 | 1/23/2012 | 11/11/2010 | 8/5/2010 |
|---|---|---|---|---|---|
Round | Acquired | Series E | Debt - II | Series D | Debt |
Amount | |||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 7 |
nContact Surgical Deal Terms
3 Deal Terms
nContact Surgical's deal structure is available for 3 funding rounds, including their Acquired from October 05, 2015.
Round | Acquired | Series D | Series B |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acquired | |||||||||||||||
Series D | |||||||||||||||
Series B |
nContact Surgical Investors
10 Investors
nContact Surgical has 10 investors. AtriCure invested in nContact Surgical's Acquired funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
10/5/2015 | 10/5/2015 | 1 Acquired | Corporation | Ohio | ||
10/11/2006 | 3/8/2013 | 5 Series B, Series C (2009), Debt (2010), Debt - II (2012), Series E (2013) | Venture Capital | North Carolina | ||
10/11/2006 | 3/8/2013 | 5 Series B, Series C (2009), Debt (2010), Debt - II (2012), Series E (2013) | Venture Capital | Tennessee | ||
Venture Capital | California | |||||
Growth Equity | Alabama |
First funding | 10/5/2015 | 10/11/2006 | 10/11/2006 | ||
|---|---|---|---|---|---|
Last Funding | 10/5/2015 | 3/8/2013 | 3/8/2013 | ||
Investor | |||||
Rounds | 1 Acquired | 5 Series B, Series C (2009), Debt (2010), Debt - II (2012), Series E (2013) | 5 Series B, Series C (2009), Debt (2010), Debt - II (2012), Series E (2013) | ||
Board Seats | |||||
Type | Corporation | Venture Capital | Venture Capital | Venture Capital | Growth Equity |
Location | Ohio | North Carolina | Tennessee | California | Alabama |
Compare nContact Surgical to Competitors
Es Vascular provides medical solutions within the cardiovascular and surgical sectors. The company offers a range of products including devices for cardiac rhythm management, electrophysiology, heart failure management, urogynecology, gynecology, gastrostomy, specialized surgery, tissue regeneration, and biopsy procedures. Es Vascular serves healthcare professionals and institutions in the medical sector. It was founded in 2000 and is based in Israel.
TransCorp develops and commercializes minimally invasive surgical instruments and implants for neurosurgical and orthopedic applications.
TissueLink Medical is a developer and distributor of medical devices that for surgical procedures. The company's technology aims to eliminate the need for multiple technologies with the potential to reduce operating room and patient recovery time by enabling precise coagulation and cutting, with no excess damage to tissue. These devices will be used in general and thoracic surgical procedures.
Focal develops, manufactures and commercializes synthetic, absorbable, liquid surgical sealants based on the company's polymer technology. The company's FocalSeal-L and FocalSeal-S surgical sealant products are currently being developed for use inside the body to seal leaks resulting from lung, neurological, cardiovascular and gastrointestinal surgery.
Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment. Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.
Medtrex develops, manufactures and markets reusable electrosurgical products and other unique surgical devices.
Loading...

